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Introduction
We live or die by blood loss. Platelets, the anuclear cells designed to stop bleeding, have 
their limits. In the past two decades, a range of intravenously administered products have 
been pursued to augment platelets and stop internal bleeding. Traumatic injury, 
thrombocytopenia, intraoperative bleeding, hemophilia, and other diseases that result in 
excessive bleeding could potentially be mitigated by this kind of product. Traumatic injury, 
for example, is a leading cause of death for young people worldwide, and many of those 
deaths are a result of excessive hemorrhage (surpassed only by CNS injury).1,2 Hemorrhage 
as a result of these traumatic injuries accounts for more than a third of prehospital mortality 
for civilians and is the leading cause of preventable deaths for soldiers.2–4 We know that 
time is absolutely critical for halting hemorrhage and saving lives: more than 80% of 
battlefield casualties and one-third of civilian trauma casualties occur before the patient ever 
reaches a hospital.2,3 This means that first responders have to be able to provide the care that 
can halt hemorrhage and keep patients alive until they can reach a hospital.
The current methods for first responders to treat patients are limited. In cases of injury to the 
extremities, tourniquets are a simple and affordable way to halt bleeding.5 Pressure and the 
use of appropriate dressings are also helpful when the injury is external.5,6 Some of the 
available dressings include the popular QuikClot, which has been shown in a pig liver injury 
model to be significantly better at reducing blood loss and improving survival when 
compared with gauze.7 One notable issue found with the first generation of this design was 
that is was highly exothermic, and was associated with tissue damage.7 Because of this, the 
mineral zeolite was replaced with kaolin, which is the currently available version of the 
product. Chitosan is another treatment that has been considered for use as a hemostatic 
agent, although the duration of efficacy in halting bleeding has been questioned.8 
Treatments that act directly on the clotting cascade have also been considered. Holcomb et 
al. showed that a fibrin sealant foam, which can be introduced into the body cavity, can 
reduce bleeding and bond with injured surfaces in a rat model.9 This type of technology 
does not rely on the ability to place direct pressure, but does still require access to the injury 
site. In addition, the fibrin is expensive and difficult to store, making it much less practical 
for field use.8 While there is no ideal dressing for hemostasis, there are many options 
currently being investigated that have significant ability to halt bleeding.
A gap remains, however, in the available treatments to halt internal bleeding. For internal 
injuries, termed noncompressible, neither dressings nor pressure and tourniquets are 
adequate solutions. This has led to study of the potential for an injectable suspension of 
particles to aid hemostasis. Such particles must act on the clotting cascade to halt bleeding 
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without activating excessive clotting, which could result in stroke or infarction. In addition, 
these particles would ideally be affordable, easily stored, and simple for field use. Several 
groups have investigated use of particles that interact with platelets or the clotting cascade to 
help aid hemostasis.
Cell-derived hemostatic agents
The clotting cascades, and primarily, platelets, were the first place that researchers looked 
for methods to halt non-compressible bleeding. Platelets are anuclear cells, derived from 
budding off from their precursor megakaryocytes, which circulate in the bloodstream in a 
quiescent state until injury occurs. They are typically 2–3 microns and are bi-discoid in their 
quiescent state. They contain alpha and dense granules, which contain pro-coagulation 
signals and clotting factors. The contents of these granules can be quickly secreted through a 
transport system called the open canalicular system.26
Primary hemostasis involves the adhesion, activation, and aggregation of platelets to form 
the platelet plug.27 When the blood vessel is injured, the damaged endothelial lining exposes 
the underlying layer subendothelium matrix28, which includes collagen29, fibronectin30, and 
laminin.31 Platelets can bind directly to this matrix through the glycoprotein GPIa/IIa 
receptor.26 However, these interactions are most effective in low shear binding.31 Under 
high shear, platelets bind mostly to von Willibrand Factor (vWF), which is itself bound to 
subendothelial matrix.32 This association is brief however, as platelet GPIb-V-IX/vWF 
binding has a very high dissociation rate. This leads to the characteristic “rolling” of 
platelets along a damaged endothelium, slowing its progress enough to allow for additional 
integrin binding to extracellular matrix proteins (e.g. GPVI-collagen or GPIa/IIa-fibrin) to 
finally arrest its motion.26
Platelets can become activated by a number of different mechanisms, including adenosine 
diphosphate (ADP), thromboxane, thrombin, and cyclooxygenase.26 Upon activation, they 
change their conformation from a bi-discoid shape to a stellate morphology. Rapid 
polymerization of actin filament in the cytoskeleton causes both the gross shape change as 
well as specific conformational change of the surface receptor glycoprogtein IIb/IIIa (GPIIb/
IIIa, integrin α2bβ3) and release of platelet alpha and dense granules.26
The change in the GPIIb/IIIa conformation exposes binding domains for both fibrinogen and 
vWF. Interestingly, fibrinogen has multiple binding domains, including the common RGD 
(arg-gly-asp) motif at each end, as well as a dodecapeptide-H12, which allows for it to act as 
a platelet-platelet bridging molecule.33–35 Upon activation, and in concert with fibrinogen, 
and other extracellular matrix (ECM) proteins, platelets rapidly aggregate, adhere to the 
injury surface, and begin to spread across the surface, such that they become 
indistinguishable from one another under scanning electron microscopy.26
Thromboerythrocytes
One of the first groups that considered this potential application for injectable particles was 
Coller et al. They looked at the use of what they called ‘thromboerythrocytes.’10 These 
particles use a peptide containing the sequence arginine-glycine-aspartic acid to bind to 
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activated platelets, which display the GPIIbIIIa receptor. This sequence was bound through 
a heterobifunctional crosslinking agent to the surface amino groups on erythrocytes. In prior 
work, they had shown how important the length of the crosslinker is for establishing 
interaction between the activated platelets and the RGD linked particles36 They were then 
able to make thromboerythrocytes that interacted selectively in vitro with platelets activated 
by the presence of ADP. This work established the importance of the RGD sequence in 
development of particles capable of interacting with activated platelets.
Synthocytes
The next group that looked at an intravenously injectable particle to improve clotting was 
Levi et al. They developed particles made of albumin coated with fibrinogen (a blood 
protein that contains the RGD sequence).11 These particles were approximately 3.5–4.5 
microns in size, larger than many of current particle formulations. They showed a reduction 
in bleed time in an in vivo ear injury model in thrombocytopenic rabbit. In this model they 
pre-injected the rabbits with the particles prior to injury. They did show with this model that 
the particles significantly reduce the bleed times of the animals, demonstrating that particles 
using the RGD sequence to bind activated platelets can, indeed, have an effect on bleeding 
outcomes.11 However, the size of these particles is problematic because particles of that size 
can be filtered in the capillary beds of the lungs.37
Thrombosomes
Another approach to the generation of particles that can perform this function is the use of 
modified platelets, which can both initiate and strengthen clotting. This is the method that 
Fitzpatrick et al. have looked at. They have shown that they can collect and freeze-dry 
platelets stabilized with trehalose in a form that is still similar to native platelets.12 The 
majority of the particles are in the 1–5 micron range (the size range of native platelets). In 
vitro studies show that the particles display GPIIbIIIa and can still perform the functions 
necessary for hemostasis. In vivo studies show that the particles stay in circulation after 
injection for the same amount of time as a normal platelet transfusion and no adverse effects 
of injection were apparent. In vivo testing with the ear bleed model in thrombocytopenic 
rabbits showed that the particles also significantly reduced blood loss.12,13 Safety testing of 
these particles was also done in a non-human primate model (rhesus macaque) without any 
adverse events reported. However, biologically derived particles may also lead to potential 
for adverse immune responses and disease transfer.38
Drugs Interacting with the Clotting Cascade
Tranexamic Acid
Tranexamic acid is a strong antagonist of plasminogen activation, and therefore acts as an 
antifibrinolytic. There is convincing evidence that its administration after trauma greatly 
improves outcomes, reducing (all cause) mortality by 23.9%-17.4%, in one study of 896 
wounded soldiers at a military hospital in Afghanistan.14,15 However, it has the potential 
drawbacks of increasing risk of diffuse intravascular coagulation, increased risk when 
administered 3–8 hours after trauma, and increased risk when co-administered with blood 
products. The concurrent use of a permissive hypotension approach may also increase 
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tranexamic acid’s risks since this approach leads to a decreased glomerular filtration rate, 
and hence a delayed clearance rate. This may lead to a change in the drug’s efficacy and 
safety.14 Nevertheless, it has tremendous potential, and may become incorporated in 
standard damage control resuscitation.39
Recombinant Factor VIIa (rFVIIa)
The administration of recombinant factor VIIa intravenously to reduce bleeding after acute 
trauma has been a topic of debate.5,19,20,40 Several studies have shown that perioperative 
administration of rFVIIa reduces the volume of blood transfusion. However, it is unclear 
whether the benefit is large enough to have any associated effect on mortality after 
hemorrhagic trauma.16–18 Its potential use in the prehospital phase is further diminished due 
to its high cost, potential for adverse effects, and necessity to be stored at 2–8 degrees 
C.18,20
Synthetic intravenous hemostats
The use of synthetic methods to generate particles has become more popular in recent years 
because they offer improved control over the final product and concerns about outcomes 
with large particles. Early studies of particle biodistribution showed that smaller particles (in 
the range of a micron or less) are taken up by the reticuloendothelial system and remain in 
the liver. Larger particles, greater than 5 microns in diameter, are mechanically filtered by 
the capillary beds of the lungs within minutes of administration.37 Particles of larger size 
were shown by Ilium et al. to cause immediate toxicity and resulted in death of rabbits 
injected with the particles within four minutes of injection.37 This filtering by the capillary 
beds is concerning and makes it doubtful that microparticles of this size would ever be 
usable in humans. This means that the ability to control size and make particles in the nano 
size range is necessary for developing a successful particle. This is of particular concern in 
the cases of cell-derived hemostatic particles. In all cases, these particles were greater than 
one micron in size.10,11,13 In that size range, the particles have the potential to cause serious 
side effects if they become trapped. Synthetic particles tend to be smaller in size, which is 
more likely to safely navigate small capillaries.21,24 This has led to more study of synthetic 
particle formulations in recent years.
Liposomes
Liposomes are a popular type of synthetic nanoparticle used primarily for drug delivery. 
Okamura et al. have developed hemostatic liposomes coated with an alternative peptide: the 
dodecapeptide HHLGGAKQAGDV (H12) which was shown in vitro to suppress platelet 
aggregation, suggesting interaction with activated platelets. The liposomes with this peptide 
are much smaller than the comparable particles derived from cells: they are typically around 
260nm in diameter (+/− 60 nm). In addition, liposomes allow encapsulation of drugs, in this 
case ADP within area enclosed by the lipid bilayer. The use of ADP there may enhance 
platelet aggregation by activation of additional platelets.22,23 These particles are entirely 
synthetic, but still offer a significant improvement in bleeding time in both 
thrombocytopenic rat and thrombocytopenic rabbit models when compared with saline as a 
treatment.22
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Bertram et al. have also shown that synthetic particles can be a functional alternative to 
particles derived from blood cells and proteins. These particles are made with a 
biodegradable polymer core (poly(lactic-co-glycolic acid) with polyethylene glycol as the 
spacer used to attach the RGD peptide. They have been shown to be effective in a rat 
femoral artery injury model at significantly reducing bleeding time.24 These particles were 
also later shown to effectively reduce lethality in a rat liver injury model by Shoffstall et 
al.25 The trend toward synthetically based particles offers several advantages. Size can be 
more easily controlled with synthetic particles and tend to be smaller, which may be an 
advantage. In addition, both the liposomes and the particles with a polymer core can be drug 
loaded to offer additional treatment at the injury site if desired.
Injury and Bleeding Models
The choice of model in these examinations is important for understanding how treatments 
may improve outcomes. In vivo models of hemostasis are generally designed to assess the 
impact of a treatment (or knockout of a specific pathway) on clotting time, blood loss, 
degree of shock, and/or survival.41 These models consist of controlled hemorrhage, 
uncontrolled hemorrhage, specific organ systems (e.g. CNS), or polytrauma.41 There are a 
variety of in vivo models that have been tested in uncontrolled hemorrhagic trauma, where 
the efficacy of a therapy such as synthetic platelets could be tested, including in rodents, 
large mammals, and non-human primates (Table 2).
Rodents
Tail, Ear Bleeding Time—Murine hemorrhagic trauma models are generally limited to 
tail bleeding times in the literature.42–44,48,50 The advantages of using mice include their 
economy and wide availability, and availability of genetically-mutated strains, and the 
associated host of immune/biochemical assays.41 However, the disadvantages are a limited 
correlation to human physiology, and an insensitivity to many coagulation defects.42 The 
latter may possibly be due to the low-flow allowing vasospasm and other compensatory 
mechanisms to allow for normal bleeding times.42 Rat models that have been investigated 
include the same bleeding time models as the mouse.51–55 However, these studies are more 
often performed to look at the physiology and response to experimental treatments.41 
Surgical procedures are technically easier to perform on the rat, blood volume is 
significantly greater, and they are still as widely available and relatively inexpensive, like 
mice.41
Lethal Liver Injury—There have also been a multitude of trauma models developed in the 
rat. One of the most widely published is a model of uncontrolled hemorrhage from a liver 
resection with or without fluid resuscitation.9,56–58 The main outcomes studied in this model 
have included blood loss, survival, and blood metabolic outcomes (oxygenation) depending 
on the resuscitation paradigm.57 The advantages include having survival as an experimental 
outcome and requiring only very simple surgery and measurement techniques.
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The disadvantages of this model include a large variability (depending strongly on rat body 
mass and liver resection).9 Rats also tend to have a higher platelet count and a relatively 
lower clotting time compared to humans.45 However, while there are moderate differences 
in hemodynamics and physiology from humans and larger animals, the coagulation cascade 
and associated mechanism appear to be relatively well-conserved: including platelet 
physiology, hepatic blood flow, and blood pressure regulation.46,47,49,59
Rabbit
Thrombocytopenia—Normal rabbit platelet counts, physiology and in vitro clotting 
parameters are extremely well-correlated to humans,45,47 making them a viable candidate 
for an in vivo model of hemorrhage, and experimental therapies. There are well-established 
protocols for inducing thrombocytopenia either chemically (busulfan)66, radiation-therapy, 
or repeat blood draws/transfusion, and have been tested in conjunction with other synthetic 
platelet treatments.11,21,22,61
Blood Loss and Bleeding Times—The majority of studies that have used the rabbit in 
a model of hemostasis have looked at bleeding times, or blood loss from surgical 
incisions.11,67–71 The limitations of bleeding times in both human and animal models is 
widely recognized.48,72 While it may produce a repeatable model, conclusions drawn must 
be limited to scope of isolated vascular injury, whereas the majority of clinical traumas are 
much more complex.42,48
Lethal Liver Injury—Recently, Nishikawa et al. have published a paper investigating the 
use of synthetic platelets to increase survival in a model of a liver trauma in 
thrombocytopenic rabbits.61 This appears to be the first lethal liver trauma model developed 
in the rabbit, and appears to induce a repeatable injury.
Pig
The pig is the standard model for uncontrolled hemorrhagic trauma, when investigating the 
physiological impact of a potential therapy.62–65,73–76 The cardiovascular system is well-
correlated with human parameters and the comparable size allows for devices to be used in 
both clinical and research environment without modification.41 Furthermore, the wound-
healing process appears to be similar to the human due to similarities between porcine and 
human skin.41 However, a porcine model is more expensive due to the equipment and need 
to for a technically-trained staff.41 Furthermore, there is an increasing body of evidence that 
suggests pigs may be especially sensitive to complement activation and related 
pseudoallergy (CARPA).77–79 Briefly, a pseudoallergy is observed after intravenous 
infusions of certain nanoparticle formulations. Symptoms include severe hypotension, 
cardiopulmonary dysfunction, and, if severe enough, death. Interestingly, other species are 
less susceptible to symptoms. However, it has been observed directly in both swine and 
dogs.79,80
Primate
Non-human primates are the best animal analog of humans available. However, this makes 
their use in medical research controversial and, due to the administrative overhead, 
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expensive. Thus, the use of primates in trauma is not well suited for establishing efficacy in 
experimental therapies, except where the anatomical/physiological differences in other 
animals precludes their use. The majority of non-human primate studies (in hemorrhagic 
trauma) are for preclinical studies, where the main goal is testing safety.
Several hemorrhagic trauma models have been established.12,81–83 Recently, of particular 
interest, Thrombosomes (a lyophilized hemostatic agent derived from platelets), underwent 
a safety study in rhesus macaques, in the presence of a hemorrhagic liver trauma.12
Challenges for Nanoparticle Formulations
There remain, however, many challenges that need to be addressed before particles such as 
those discussed above can be translated for use by first responders. While micro- and 
nanoparticles appear to offer many advantages for targeting and drug delivery, there are key 
issues of stability and evasion of the immune system that must be addressed.
Blood Circulation Time
The adsorption of proteins is also a significant concern for any surface or particle that will 
contact blood because it is believed to cause rapid uptake of particles by the RES system. It 
is well understood that when the surface of a biomaterial is put into the body, it is 
immediately covered with a protein corona.85,86 Understanding the degree to which 
nanoparticles will be taken up by phagocytosis and maximizing evasion of the RES system 
are considered necessary for the success of nanoparticle treatments. In addition, the 
formation of the protein corona alters the interaction of nanoparticles with their 
environments, which may effect the ability of nanoparticles targeted to activated platelets to 
interact with their receptors.85,86 PEGylation of nanoparticles is the most typical method 
used to attempt to overcome protein adsorption. It has been shown that for polymeric 
nanoparticles, PEG content between 2 and 5 weight %, with a PEG molecular weight of 
5000 grams/mole is optimal for prevention of protein adsorption.87 Even with the use of 
PEG to prevent protein adsorption, there will still be protein adsorption, and the result is that 
these types of nanoparticles will have a relatively short circulation time.
Storage and Resuspension (stability)
Particle stability in storage is another concern for successfully translating particles to a 
clinical setting. The need for refrigeration significantly hurts the chances that a technology 
will be successful in a military setting or useful for first responders. Alternative treatments, 
such as blood transfusions and rVIIa require refrigeration, which is a significant impediment 
to use in the field. Some of the proposed treatment can be stored at ambient temperatures, 
such as the thrombosomes.13 Storage of liposomes has proven challenging. They are most 
easily stored in suspension, which is stable for several months when refrigerated.88 They can 
be stored longer by freeze drying, but will still suffer degradation, and keep best when 
maintained at cold temperatures, although they do have a glass transition in the range of up 
to 40 °C, beyond which no particle structure would be expected to be maintained.89,90
Polymers offer a potentially more stable solution. Polymeric nanoparticles are most often 
freeze-dried, which is more stable than storage in aqueous solution.88 While PLGA, used by 
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Bertam and Shoffstall et al., has a relatively low glass transition temperature of around 40 
°C, PLA, another polymer used frequently for nanoparticle formulation, is an alternative 
polymer that has a higher glass transition of 50 °C, which could offer a solution to 
temperature degradation. It is also crystalline, which offers additional stability, and will 
form stereocomplexes when both L- and D- lactide polymers are present.91,92
Nanoparticles are stored in suspension, frozen, or as a lyophilized product, depending on 
their stability in each phase. For biodegradable polymer nanoparticles, they are generally 
lyophilized for long-term storage. However, due to crystallization during processing, 
aggregates are formed, which then require sonication in order to recover pre-lyophilization 
size distributions.93 This has led to the development and use of cryo- and lyo-protectants. 
Some of these involve sugars such as trehalose and sucrose, polymers PVA, poly(vinyl 
pyrrolidone) (PVP), and even matrices, such as gelatin.88 Some concerns exist as to the 
concentrations of these excipients required in order to stabilize nanoparticles, for example a 
1:1 w/w ratio in the case of trehalose, which could constitute a substantial dose of sugar 
depending on the application.88 While trehalose has been shown to be safe at oral doses up 
to 50g, its metabolism with i.v. delivery may require further investigation in regards to 
safety and toxicity.94 The use of surfactants such as Tween 80 (polysorbate 80), and other 
excipients are used to minimize the energy required to resuspend nanoparticles after 
lyophliiziation, however toxicity is always a potential concern.95
Complement activation
Complement activation related pseudoallergy (CARPA) is elicited readily in pigs during 
administration of certain liposomes and several polymeric-based nanoparticles.77 The 
hallmark symptoms of CARPA appear within 1–3 minutes following particle administration 
and include cardiopulmonary distress (including increase in heart rate, hypotension, 
decreased cardiac output, decreased pulmonary pressures, and decreased blood gas levels), 
and a characteristic flushing of the skin (erythema) upon reperfusion of the tissues.77–79 
Surprisingly, unless symptoms are so severe they lead to mortality, these issues 
spontaneously resolve within minutes. Regardless, the consequences of a severe CARPA 
episode during administration of intravenous hemostats could be catastrophic, and the 
mitigation by pharmaceutical prophylaxis is likely contraindicated. Therefore, the 
development of robust models to ensure a minimized risk for CARPA during nanoparticle 
administration, and elucidating its mechanisms so that patient-exclusion criteria, based on 
heighted risk factors, will be paramount to the clinical translation of intravenous hemostatic 
technologies.
Complement activation is classically induced by traumas, invading bacteria, and viruses; 
experimentally, it is induced with endotoxin lipopolysaccharide (LPS). Pigs, compared to 
humans, are especially sensitive to CARPA, endotoxemia and sepsis, which make them 
good models for those pathologies.96 Administration of Doxil (a liposome-based 
chemotherapeutic) causes mild-to-moderate hypersensitivity reactions in 0–25% of 
humans97, sometimes even subclinically, yet causes moderate-to-lethal reactions in swine.98 
Interestingly, drastic response to nanoparticles in mice and rat models are not readily 
observed, making them very poor models for detecting CARPA. It is most likely, as has 
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been previously reported, that the pig species simply has a heightened immune response to 
pathogens, potentially due to their selective breeding in the meat industry, where 
susceptibility to disease has been strongly selected against.96
While these reactions are thought to be pseudoallergies, in at least one study, repeat 
administrations (of a novel pegylated micelle) increased the severity of reactions, measured 
by histamine release and complement activation, consistent with antibody-mediated 
reactions.99,100 Since the precise mechanism has not yet been elucidated, methods to design 
around this adverse reaction are also somewhat poorly understood. Three main strategies 
have been employed to date: prophylaxis, tachyphylaxis, and tuning surface chemistry.
Mitigation of response
Prophylaxis—Szebeni et al.78,77 describes the nonspecific complement activation to 
infusions of nanoparticle drug carrier systems and discuss that the reaction can be prevented 
with preconditioning with low doses of the nanoparticle carrier or pharmacologically with 
indomethacin (a potent complement inhibitor).
Diphenhydramine, phenylephrine, epinephrine and steroids may also be used in conjunction 
to reverse the anaphylaxis induced by CARPA.79 Unfortunately for the application of 
intravenous hemostatic agents to be administered during trauma, co-administration with 
additional pharmaceuticals should be avoided if possible.
Tachyphylaxis—One potential method for reducing the onset of CARPA is to infuse the 
nanoparticles slowly (or with multiple small doses) (tachyphylaxis)78 This appeared to 
prevent the onset of CARPA and reduce the severity of any symptoms. It relies on a 
desensitization mechanism. However, since the present therapy will rely on rapid 
administration after hemorrhagic injury, tachyphylaxis does not appear to be a viable option.
Tuning particle charge—Currently, the most viable option for prevention of CARPA 
appears to be tuning the surface chemistry of the nanoparticles to have a neutral zeta 
potential.98 While the symptoms appear to be exaggerated in pigs, there does appear to be a 
large human population of individuals that experience CARPA symptoms, when 
administered the novel liposomal chemotherapeutic Doxil.97 In one particular study, a post-
hoc analysis demonstrated that 45% of patients receiving Doxil showed symptoms of 
CARPA (grade 2 and 3), where grade 2 is symptomatic but does not require intervention, 
and grade 3 is a severe reaction requiring anti-allergic medication and cessation of the 
infusion. The responding population received infusions at a mean rate of 0.51 mg/min, with 
a mean total 151.8 mg, compared to those that showed no symptoms, receiving a mean 
infusion rate of 0.23 mg/min, total 70.1 mg.97 However, it is important to note that even in 
patients not showing symptoms, complement activation (SC5b-9 elevation) is present, which 
may aggravate other pathways during trauma.97 While the infusion rate of 0.2 mg/min (or 
tachyphylaxis) may be an acceptable method to mitigate the induction of CARPA for 
chemotherapy, this is not an acceptable practice for intravenous hemostat applications, 
where a large bolus is attempting to be infused as quickly as possible to prevent blood loss.
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Bleeding resulting from traumatic injury remains a leading cause of death for young people. 
There are few treatments that first responders can offer for non-compressible bleeding, but 
nanoparticles are being investigated as a way to fill this gap in treatment. These treatments 
typically use peptide sequences to bind to activated platelets and crosslink them to stabilize 
the platelet plug. Research in this area has evolved from biologically based microparticles 
towards synthetic nanoparticles. Reduction in size and use of appropriate synthetic materials 
can improve circulation time and reduce the risks associated with larger particles. However, 
there are still concerns about protein adsorption, immune response, and stability of this type 
of particle that must be overcome before these particles can be translated for clinical use.
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Summary of Intravenous Hemostat Designs including thromboerythrocytes (Arginine-
Glycine-Aspartic Acid (RGD) decorated red blood cell fragements), synthocytes (fibrinogen 
coated albumin particles), liposomes coated with H12 and PLGA-PEG nanoparticles 
decorated with RGD.
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Table 1
Summary of experimental substitutes, their efficacy, and references.
Cell derived substitutes Results References:
Thromboerythrocytes In vitro demonstration the interaction of activated platelets with RGD linked to red blood cell 
fragment
10
Synthocytes Reduction in bleeding time of ear bleed and surgical incision bleed in thrombocytopenic rabbits 11
Thrombosomes Retention of normal expression of GPIIbIIIa and normal aggregation. Reduction in blood loss in 
ear bleed model of thrombocytopenic rabbits.
12,13
Drugs:
Tranexamic Acid Improves outcomes in battlefield mortality, however there is evidence of risk of diffuse 
intravascular coagulation.
14,15
Recombinant Factor VIIa Reduces bleeding after acute trauma to a small degree, but has potential for adverse effects and is 
difficult to store appropriately
16–20
Synthetic substitutes:
Liposomes Reduced bleeding time in thrombocytopenic rat and rabbit bleeding models 21–23
PLGA Nanoparticles Reduction in bleed time in rat femoral artery injury. Increased survival in rat liver injury model. 24,25
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Table 2
Advantages and disadvantages of various species in bleeding hemorrhagic trauma models.
Species Advantages Disadvantages Refs.
Mouse Economy, wide availability of genetically-mutated strains, 
and the associated host of immune/biochemical assays
High platelet count, limited correlation to 
human physiology, and an insensitivity to 
many coagulation defects, small size makes 
some interventions technically challenging
42–47
Rat Similar to mouse, surgical procedures are technically easier 
to perform on the rat, and they are still as widely available 
and relatively cheap like mice. The coagulation cascade and 
associated mechanism appear to be relatively well-conserved: 
including platelet physiology, hepatic blood flow, and blood 
pressure regulation
High platelet count and a relatively lower 
clotting time compared to humans, small size 
still presents some technical challenges
22–24,45–60
Rabbit Platelet counts, physiology and in vitro clotting parameters 
are extremely well-correlated to humans, making them a 
viable candidate for an in vivo model of hemorrhage, and 
experimental therapies.
More expensive and fewer on-shelf bio-assays 
than rats or mice, insensitive to thrombin 
receptor peptides that activate human platelets.
12,45–47,59–61
Pig The cardiovascular system is well-correlated with human 
parameters and the comparable size allows for devices to be 
used in both clinical and research environment without 
modification. Wound-healing process appears to be similar to 
the human due to similarities between porcine and human 
skin.
Expensive, need technically-trained staff, 
sensitivity to complement activation related 
pseudoallergy (CARPA).
41,45–47,62–65
Primate Best animal analog of humans available. Controversial, very expensive, highly 
regulated. These studies are generally 
performed prior to initiating a clinical trial to 
test for safety/efficacy.
13,46,47
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Table 3
Common hemorrhagic injury models with advantages, disadvantages and example references.
Model Advantages Disadvantages Refs.
Bleeding time (tail, ear, 
isolated vessel)
*Survival time, rather than 
bleed time is main 
outcome
Simple, easy to perform and measure. Blood 
loss as well as bleeding time and survival time 
are common outomes
Limited correlation to survival, and 







Liver trauma Simple, easy to perform, blood loss and 
survival as main outcomes, potentially better 
correlation to functional outcomes
May require larger number of 






Polytrauma Clinically relevant Technically difficult, requires trained 
staff
Pig 41,62,63,65
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